Bausch & Lomb (Bausch & Lomb) Current Accrued Expense : $595 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Current Accrued Expense?

Bausch & Lomb's Current Accrued Expense for the quarter that ended in Mar. 2024 was $595 Mil.

Bausch & Lomb's quarterly Current Accrued Expense increased from Sep. 2023 ($283 Mil) to Dec. 2023 ($394 Mil) and increased from Dec. 2023 ($394 Mil) to Mar. 2024 ($595 Mil).

Bausch & Lomb's annual Current Accrued Expense increased from Dec. 2021 ($224 Mil) to Dec. 2022 ($363 Mil) and increased from Dec. 2022 ($363 Mil) to Dec. 2023 ($394 Mil).

Bausch & Lomb Current Accrued Expense Historical Data

The historical data trend for Bausch & Lomb's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Current Accrued Expense Chart

Bausch & Lomb Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

211.00

199.00

224.00

363.00

394.00

Bausch & Lomb Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial												269.00	679.00	283.00	394.00	595.00

Bausch & Lomb Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Bausch & Lomb Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch & Lomb (Bausch & Lomb) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (NYSE:BLCO) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

S2L:Germany BLCO:Canada

Address

520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4

Website

https://www.bausch.com

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Executives

Luc Bonnefoy	officer: President,Surgical	C/O BAUSCH + LOMB CORPORATION, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Andrew J. Stewart	officer: See remarks	C/O BAUSCH + LOMB CORPORATION, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Bailey A Robert D	officer: EVP & Chief Legal Officer	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Brent L Saunders	director, officer: CEO and Chair	2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Brett Icahn	director	C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Gaoxiang Hu	director	16690 COLLINS AVE., SUITE PH-1, SUNNY ISLES BEACH FL 33160
Bausch Health Companies Inc.	10 percent owner	2150 ST. ELZEAR BLVD. WEST, LAVAL, QUEBEC A8 H7L 4A8
Sarah B Kavanagh	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Nathalie D. Bernier	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Yehia Hashad	officer: EVP, R&D and CMO	C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Frederick Munsch	officer: SVP, Controller and CAO	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Joseph F Gordon	officer: Please see remarks	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Ross Thomas W. Sr.	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Christina Ackermann	officer: Please see remarks	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Russel C Robertson	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807